AcuCort’s first approved drug, ISICORT®, has been approved in Sweden for, among other things, the treatment of acute and severe allergic reactions, croup in children, nausea and vomiting during chemotherapy. In February 2021 the drug was also approved for the treatment of patients with COVID-19 with breathing difficulties and need for oxygen therapy.
The goal is to commercialize ISICORT® globally, that is, in the EU, the US and selected key markets. The company’s strategy is to attract partners with regional or global market presence as well as expertise and resources to quickly launch ISICORT® after regulatory approval. Dialogues with potential partners in prioritized markets are ongoing.